SoniVie developed a novel Intra-Vascular Ultrasound (TIVUS) System for the treatment of various hypertensive disorders.
TIVUS System is designed for the treatment of resistant hypertension. Resistant hypertension is a form of hypertension where, despite being treated with three or more antihypertensive medications, the patient’s systolic blood pressure remains over 140 mmHg.
Hypertension increases the risk of heart attack, stroke, and kidney failure in millions of people across the globe.
Ultrasound-based denervation technology can provide better clinical outcomes without lacking medical management. TIVUS System combined with existing treatments will advance the clinical outcomes.
Renal denervation carried out with the TIVUS system is a minimally invasive procedure that uses high-frequency, non-focused ultrasound to remove nerves in the renal artery. This procedure is designed for patients who suffer from resistant hypertension to reduce the nerve activity, which decreases blood pressure.
U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the TIVUS System for Renal Artery Denervation.
